ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro

September 20, 1991

Cytyc Buys Pro-Duct Health, Ductal Lavage Device Maker. TAP To Pay $875 Million To Settle Federal Civil Suit.

October 26, 2001

Study: Keytruda Improves PFS In Ipilimumab-Refactory Disease

November 28, 2014

UC Davis Study Finds Patients Need Practical Information

June 28, 2002

DCBD To Increase Emphasis On Workshops, Cut Program Initiatives

November 8, 1985

FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.

March 31, 2000